Market Access Lilly EVP: VPAG Deadline Probably Postponed Another Two Week... For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.
Market Access Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go... Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.
Market Access HES data: The UK’s powerful source of real-world evidence HES data not only supports the effective management of health and care services, but it can also power clinical research and innovation.
Market Access Smoothing a contract pathway through uncertainty: In convers... Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.
Market Access Sponsored The stealth market access strategy that’s quietly making man... There is an under-the-radar market access strategy that some manufacturers have implemented, but many others remain unaware of.
Market Access Beyond the Bill: how do we make medicines affordable without... Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.